Glassman Wealth Services’s Blueprint Medicines BPMC Stock Holding History

Glassman Wealth Services’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5	Closed	-$461	–	431
2023 Q4	$461	Hold	5	–	–	﹤0.01%	1736
2023 Q3	$251	Hold	5	–	–	﹤0.01%	1850
2023 Q2	$316	Hold	5	–	–	﹤0.01%	1729
2023 Q1	$225	Buy	+5	New	+$225	﹤0.01%	1772
2022 Q4	–	Sell	-9	Closed	-$1K	–	1938
2022 Q3	$1K	Hold	9	–	–	﹤0.01%	1343
2022 Q2	$0	Sell	9 -10	-53%	-$586	﹤0.01%	1687
2022 Q1	$1K	Buy	19 +10	+111%	+$718	﹤0.01%	1343
2021 Q4	$1K	Hold	9	–	–	﹤0.01%	1315
2021 Q3	$1K	Hold	9	–	–	﹤0.01%	1291
2021 Q2	$1K	Hold	9	–	–	﹤0.01%	1242
2021 Q1	$1K	Hold	9	–	–	﹤0.01%	1202
2020 Q4	$1K	Hold	9	–	–	﹤0.01%	1163
2020 Q3	$1K	Hold	9	–	–	﹤0.01%	1104
2020 Q2	$1K	Sell	9 -1	-10%	-$68	﹤0.01%	965
2020 Q1	$1K	Sell	10 -6	-38%	-$386	﹤0.01%	815
2019 Q4	$1K	Buy	16 +3	+23%	+$225	﹤0.01%	863
2019 Q3	$1K	Hold	13	–	–	﹤0.01%	794
2019 Q2	$1K	Buy	+13	New	+$1.07K	﹤0.01%	805

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glassman Wealth Services's BPMC Position: Q1 2024 in Review

Glassman Wealth Services sold out of Blueprint Medicines (BPMC) in Q1 2024, closing a stake of 5 shares — an estimated $461 sold.

Glassman Wealth Services first reported a position in BPMC in Q2 2019 and held it in 18 quarters. The position peaked at $1K in Q3 2022. 283 funds tracked by Wall St. Rank hold BPMC as of Q1 2024.

Glassman Wealth Services reported no remaining Blueprint Medicines position as of Q1 2024 after selling out during the quarter.
Glassman Wealth Services sold 5 Blueprint Medicines shares in Q1 2024, an estimated $461.
Glassman Wealth Services first reported a position in Blueprint Medicines in Q2 2019 and held it in 18 quarters.
Glassman Wealth Services's Blueprint Medicines position peaked at $1K in Q3 2022.
283 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.